Asher Chanan-Khan, MD, Oncology, Jacksonville, FL, Mayo Clinic Hospital in Florida

AsherChanan-KhanMD

Oncology Jacksonville, FL

Hematologic Oncology

Professor of Medicine, Mayo Clinic School of Medicine

Dr. Chanan-Khan is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Chanan-Khan's full profile

Already have an account?

Summary

  • Dr. Asher Chanan-Khan is an oncologist in Jacksonville, FL and is affiliated with Mayo Clinic Hospital in Florida. He received his medical degree from Allama Iqbal Medical College and has been in practice 24 years. He also speaks multiple languages, including Punjabi, Hindi, and Urdu. He specializes in hematologic oncology and is experienced in CLL, Waldenstrom Macroglobulinemia, hematologic oncology, and multiple myeloma.

Education & Training

  • NYU School of MedicineFellowship, Hematology, 1999 - 2000
  • NYU School of MedicineFellowship, Medical Oncology, 1998 - 1999
  • NYU School of MedicineFellowship, Hematology, 1997 - 1998
  • Harlem Hospital CenterResidency, Internal Medicine, 1994 - 1997
  • Allama Iqbal Medical CollegeClass of 1993

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2011 - 2022
  • NY State Medical License
    NY State Medical License 2002 - 2021
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Healthcare Heroes Jacksonville Business, 2016
  • America's Top Doctors Castle Connolly, 2009-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
    Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Asher A. Chanan-Khan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Ibrutinib Regimen Improves PFS by 80% in Phase III CLL Study
    Ibrutinib Regimen Improves PFS by 80% in Phase III CLL StudyMay 30th, 2015

Professional Memberships

Other Languages

  • Punjabi, Hindi, Urdu

Hospital Affiliations

Industry Relationships

  • Clinical Trial Principal Investigator, Jansen
  • Clinical Trial Principal Investigator, Celgene